<p>CG Oncology, Inc.（纳斯达克股票代码：CGON - 获取免费报告）的股价周四下跌了 0.9%。股价最低下跌至 29.26 美元，最后交易价为 30.25 美元。交易中约有 408,077 股股票交易，较平均每日成交量 672,452 股下降了 39%。该股之前收盘价为 30.52 美元。</p>
<h2>分析师设定新的价格目标</h2>
<p>一些股票研究分析师最近发布了关于 CGON 股票的报告。高盛集团将 CG Oncology 的股票评级从 “中性” 调高至 “买入”，并在 5 月 13 日星期一的研究报告中将公司的价格目标从 43.00 美元上调至 50.00 美元。康泰菲兹（Cantor Fitzgerald）重申了对 CG Oncology 的 “超重” 评级，并在 5 月 2 日星期四的研究报告中设定了 75.00 美元的目标价。最后，HC Wainwright 重申了对 CG Oncology 的 “买入” 评级，并在 5 月 28 日星期二的报告中设定了 75.00 美元的价格目标。</p>
<p><strong>阅读我们关于 CG Oncology 的最新报告</strong></p>
<h2>CG Oncology 股价下跌 0.9%</h2>
<p>该股票的五十日移动平均价格为 33.57 美元。</p>
<p>CG Oncology（纳斯达克股票代码：CGON - 获取免费报告）最近发布了其季度财报，日期为 5 月 9 日星期四。公司报告该季度每股收益（EPS）为-0.36 美元，低于预期的-0.35 美元。该季度公司的营收为 530 万美元。分析师们预计，CG Oncology, Inc.今年将实现-1.71 美元的每股收益。</p>
<h2>对 CG Oncology 进行投资的对冲基金发表意见</h2>
<p>机构投资者和对冲基金最近对该股票的持仓进行了调整。Ameritas 投资合作伙伴公司在第一季度收购了 CG Oncology 的新头寸，价值约 10.2 万美元。加州州立教师退休金系统在第一季度收购了价值约 10.3 万美元的 CG Oncology 新头寸。法国巴黎银行金融市场在第一季度收购了价值约 49.2 万美元的 CG Oncology 新头寸。Capstone 投资顾问有限责任公司在第一季度收购了价值约 80.6 万美元的 CG Oncology 新头寸。最后，Blackstone Inc.在第一季度收购了价值约 109.8 万美元的 CG Oncology 新头寸。26.56% 的股票由机构投资者和对冲基金持有。</p>
<h2>CG Oncology 公司简介（获取免费报告）</h2>
<p>CG Oncology, Inc.是一家肿瘤溶解免疫疗法公司，专注于为膀胱癌患者开发和商业化骨干膀胱保留治疗方案。该公司开发了 BOND-003，用于治疗高风险的卡介苗不敏感的非肌层侵袭性膀胱癌（NMIBC）患者；CORE-001 用于治疗高风险的卡介苗不敏感的 NMIBC 患者，与 pembrolizumab 联合使用；CORE-002 用于治疗肌层侵袭性膀胱癌患者，与检查点抑制剂 nivolumab 联合使用。</p>
<h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 CG Oncology 更好</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>BlackBerry 股票：强劲的盈利，前方挑战</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Progress Software 股票在超过预期后重回上涨</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>高盛集团为 Affirm 提高股价目标：关键见解</li>
</ul>
<p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<p>→ 伊隆的下一个 IPO 可能比特斯拉还要大（来自 Paradigm Press）（广告）</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw"/></p>
<h2>您现在是否应该投资 1000 美元购买 CG Oncology 股票？</h2>
<p>在考虑 CG Oncology 之前，您可能希望听听这个。</p>
<p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 CG Oncology 并不在这份名单上。</p>
<p>尽管 CG Oncology 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>查看这五只股票</p>

CGON

<p>CG Oncology（纳斯达克股票代码：CGON）周四股价下跌了 0.9%，最低交易价为 29.26 美元。分析师已经设定了新的价格目标，机构投资者也对该股票的持仓进行了调整。CG Oncology 专注于开发和商业化针对膀胱癌患者的脊柱膀胱保留治疗方案</p>

<p>CG Oncology, Inc. (NASDAQ:CGON - Get Free Report)'s stock price was down 0.9% on Thursday . The stock traded as low as $29.26 and last traded at $30.25. Approximately 408,077 shares were traded during trading, a decline of 39% from the average daily volume of 672,452 shares. The stock had previously closed at $30.52.</p>
<div class="lb-trans"><p>CG Oncology, Inc.（纳斯达克股票代码：CGON - 获取免费报告）的股价周四下跌了 0.9%。股价最低下跌至 29.26 美元，最后交易价为 30.25 美元。交易中约有 408,077 股股票交易，较平均每日成交量 672,452 股下降了 39%。该股之前收盘价为 30.52 美元。</p>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新的价格目标</h2>
</div><p>A number of equities research analysts recently issued reports on CGON shares. The Goldman Sachs Group raised shares of CG Oncology from a &#34;neutral&#34; rating to a &#34;buy&#34; rating and lifted their price target for the company from $43.00 to $50.00 in a research note on Monday, May 13th. Cantor Fitzgerald reaffirmed an &#34;overweight&#34; rating and set a $75.00 target price on shares of CG Oncology in a research note on Thursday, May 2nd. Finally, HC Wainwright reiterated a &#34;buy&#34; rating and set a $75.00 price target on shares of CG Oncology in a report on Tuesday, May 28th.</p>
<div class="lb-trans"><p>一些股票研究分析师最近发布了关于 CGON 股票的报告。高盛集团将 CG Oncology 的股票评级从 “中性” 调高至 “买入”，并在 5 月 13 日星期一的研究报告中将公司的价格目标从 43.00 美元上调至 50.00 美元。康泰菲兹（Cantor Fitzgerald）重申了对 CG Oncology 的 “超重” 评级，并在 5 月 2 日星期四的研究报告中设定了 75.00 美元的目标价。最后，HC Wainwright 重申了对 CG Oncology 的 “买入” 评级，并在 5 月 28 日星期二的报告中设定了 75.00 美元的价格目标。</p>
</div><p><strong>Read Our Latest Report on CG Oncology</strong></p>
<div class="lb-trans"><p><strong>阅读我们关于 CG Oncology 的最新报告</strong></p>
</div><h2>CG Oncology Trading Down 0.9 %</h2>
<div class="lb-trans"><h2>CG Oncology 股价下跌 0.9%</h2>
</div><p>The stock's fifty day moving average price is $33.57.</p>
<div class="lb-trans"><p>该股票的五十日移动平均价格为 33.57 美元。</p>
</div><p>CG Oncology (NASDAQ:CGON - Get Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.35) by ($0.01). The company had revenue of $0.53 million for the quarter. As a group, analysts forecast that CG Oncology, Inc. will post -1.71 EPS for the current year.</p>
<div class="lb-trans"><p>CG Oncology（纳斯达克股票代码：CGON - 获取免费报告）最近发布了其季度财报，日期为 5 月 9 日星期四。公司报告该季度每股收益（EPS）为-0.36 美元，低于预期的-0.35 美元。该季度公司的营收为 530 万美元。分析师们预计，CG Oncology, Inc.今年将实现-1.71 美元的每股收益。</p>
</div><h2>Hedge Funds Weigh In On CG Oncology</h2>
<div class="lb-trans"><h2>对 CG Oncology 进行投资的对冲基金发表意见</h2>
</div><p>Institutional investors and hedge funds have recently made changes to their positions in the stock. Ameritas Investment Partners Inc. acquired a new position in shares of CG Oncology during the first quarter worth about $102,000. California State Teachers Retirement System acquired a new position in CG Oncology in the first quarter valued at approximately $103,000. BNP Paribas Financial Markets acquired a new position in CG Oncology in the first quarter valued at approximately $492,000. Capstone Investment Advisors LLC acquired a new position in CG Oncology in the first quarter valued at approximately $806,000. Finally, Blackstone Inc. acquired a new position in CG Oncology in the first quarter valued at approximately $1,098,000. 26.56% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>机构投资者和对冲基金最近对该股票的持仓进行了调整。Ameritas 投资合作伙伴公司在第一季度收购了 CG Oncology 的新头寸，价值约 10.2 万美元。加州州立教师退休金系统在第一季度收购了价值约 10.3 万美元的 CG Oncology 新头寸。法国巴黎银行金融市场在第一季度收购了价值约 49.2 万美元的 CG Oncology 新头寸。Capstone 投资顾问有限责任公司在第一季度收购了价值约 80.6 万美元的 CG Oncology 新头寸。最后，Blackstone Inc.在第一季度收购了价值约 109.8 万美元的 CG Oncology 新头寸。26.56% 的股票由机构投资者和对冲基金持有。</p>
</div><h2>CG Oncology Company Profile (Get Free Report)</h2>
<div class="lb-trans"><h2>CG Oncology 公司简介（获取免费报告）</h2>
</div><p>CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.</p>
<div class="lb-trans"><p>CG Oncology, Inc.是一家肿瘤溶解免疫疗法公司，专注于为膀胱癌患者开发和商业化骨干膀胱保留治疗方案。该公司开发了 BOND-003，用于治疗高风险的卡介苗不敏感的非肌层侵袭性膀胱癌（NMIBC）患者；CORE-001 用于治疗高风险的卡介苗不敏感的 NMIBC 患者，与 pembrolizumab 联合使用；CORE-002 用于治疗肌层侵袭性膀胱癌患者，与检查点抑制剂 nivolumab 联合使用。</p>
</div><h2>Featured Stories</h2>
<ul>
<li>Five stocks we like better than CG Oncology</li>
<li>Russell 2000 Index, How Investors Use it For Profitable Trading</li>
<li>BlackBerry Stock: Strong Earnings, Profitability Challenges Ahead</li>
<li>How Can Retail Investors Trade the Toronto Stock Exchange (TSX)?</li>
<li>Progress Software Stock Back in the Green After Beating Forecasts</li>
<li>How to Use the MarketBeat Excel Dividend Calculator</li>
<li>Goldman Sachs Raises Stock Target for Affirm: Key Insights</li>
</ul>
<div class="lb-trans"><h2>精选故事</h2>
<ul>
<li>我们喜欢的五只股票，比 CG Oncology 更好</li>
<li>Russell 2000 指数，投资者如何利用它进行盈利交易</li>
<li>BlackBerry 股票：强劲的盈利，前方挑战</li>
<li>零售投资者如何交易多伦多证券交易所（TSX）？</li>
<li>Progress Software 股票在超过预期后重回上涨</li>
<li>如何使用 MarketBeat Excel 股息计算器</li>
<li>高盛集团为 Affirm 提高股价目标：关键见解</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙事科技和 MarketBeat 的财务数据生成，旨在为读者提供最快速和最准确的报道。本故事在发布前已经由 MarketBeat 的编辑团队进行了审查。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><p>→ Elon’s Next IPO Could be Bigger than Tesla (From Paradigm Press)(Ad)</p>
<div class="lb-trans"><p>→ 伊隆的下一个 IPO 可能比特斯拉还要大（来自 Paradigm Press）（广告）</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD04NTEw" alt="" original-src="https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx?TriggeredCampaignID=8510&amp;Placement=NativeDisplay&amp;Source=NativeDisplay"/></p>
<h2>Should you invest $1,000 in CG Oncology right now?</h2>
<div class="lb-trans"><h2>您现在是否应该投资 1000 美元购买 CG Oncology 股票？</h2>
</div><p>Before you consider CG Oncology, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 CG Oncology 之前，您可能希望听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CG Oncology wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街评级最高且表现最佳的研究分析师以及他们推荐给客户的股票。MarketBeat 已经确定了五只顶级分析师悄悄告诉客户在更广泛市场注意之前现在购买的股票...而 CG Oncology 并不在这份名单上。</p>
</div><p>While CG Oncology currently has a &#34;Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>尽管 CG Oncology 目前在分析师中有 “买入” 评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看这五只股票</p>
</div>

CG Oncology（纳斯达克代码：CGON）股价下跌 0.9%